Novartis' new Gilenya data fails to address NICE concerns as final decision looms
This article was originally published in Scrip
Executive Summary
Novartis has released a basket of clinical and preclinical data to support Gilenya (fingolimod), the first oral treatment for multiple sclerosis that was approved in the US last year and in the EU in March 2011. The firm has collated a range of data under the headline figure that the drug has had "more than 20,000 patient-years of exposure", making the announcement at a critical point in the product's European career.